# OMass Therapeutics: Research, Oxford, United Kingdom

> OMass Therapeutics: OMass Therapeutics is a biotechnology company located in Oxford, UK, focused on discovering and developing novel small molecule...

Source: https://millionrounds.com/startup/omass-therapeutics (Millionrounds; every figure on the page links to its filing or article)

United Kingdom · [Research startup](https://millionrounds.com/companies)

# OMass Therapeutics

OMass Therapeutics is a biotechnology company located in Oxford, UK, focused on discovering and developing novel small molecule medicines for rare diseases and immunological conditions.

Funding reported Last round: Series B

Research Oxford, United Kingdom

Company summary

- **Founded:** 2016 10 years old
- **Team:** 75 51 to 200 people
- **Funding reported:** 128M as listed, currency not stated
- **Last round:** Series B May 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for OMass Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About OMass Therapeutics

OMass Therapeutics is a biotechnology company located in Oxford, UK, focused on discovering and developing novel small molecule medicines for rare diseases and immunological conditions.

Founded in 2016 as a spin-out from Oxford University by Prof. Dame Carol Robinson and others, OMass utilizes advanced techniques like native mass spectrometry and custom chemistry to study complex biological targets in their natural environments. The company operates at the pre-clinical stage and has developed a proprietary drug discovery platform called OdyssIONTM, which allows for high-resolution analysis of protein interactions. This platform helps identify drug candidates that can effectively modulate complex formations. OMass is also engaged in collaborations with major pharmaceutical companies, including an exclusive agreement with Genentech to develop therapies for inflammatory bowel disease. With a strong focus on addressing high unmet medical needs, OMass aims to provide innovative solutions for patients suffering from rare immunological and genetic disorders.

## What company datasets say OMass Therapeutics raised

Funding, as reported

Reported in all **128M** in the source's currency

Rounds **5**

Last round **Series B**

Last round size **13.2M**

Last round date **May 2023**

Investors listed **7**

## Funding filed with regulators

OMass Therapeutics filed 5 raises, $127M in all. Filings say how much was sold and to how many investors; they never name the investors.

- Sept 2026 **$53M** UK share allotment
- Jul 2024 **$44M** UK share allotment
- Apr 2023 **$7.5M** UK share allotment
- Mar 2022 **$10M** UK share allotment
- Aug 2021 **$12M** UK share allotment

## Founders and team

From OMass Therapeutics's own website: 3 founders, 14 on the team.

**Jonathan Hopper** Vice President, Platforms and Founder

**Idlir Liko** Founder

**Working Here** Founder

- **Rosamond Deegan** Chief Executive Officer
- **Jon Roffey** Senior Vice President of Discovery and Non-Clinical
- **Steve Griffen** Vice President, Clinical Development
- **Melissa Faris** Chief Business Officer
- **Professor Steven Charlton** Chief Scientific Officer
- **Carol Schafer** Non-executive Director
- **Chris Ashton** Non-executive Director
- **Diana Bernstein** Non-executive Director
- **Edward Hodgkin** Non-executive Director
- **Jonathan Montagu** Chairman
- **Laia Crespo** Non-executive Director
- **Nathalie Franchimont** Non-executive Director
- **Pierre Joffrin** Non-executive Director
- **Scott Biller** Non-executive Director

Advisers *Professor Dame Carol Robinson*

## The company, in detail

What they build

Known for

health care biotechnology research small molecule therapeutics protein complexes pharmacology solute carriers medical research custom chemistry drug development platform orphan disease therapeutics immunological diseases hospital & health care inflammasome targeting target engagement assays gpcr drug discovery medical

Built with from their website

Google Maps Google Tag Manager WordPress.org Spectro Font Awesome MailChimp CloudFlare Viewport Meta TrustArc CookieYes

+8 more

Amazon S3 Apple Business Manager Google Maps Platform KnowBe4 Priority Hints CAPTCHA Google Font API Microsoft Exchange

- **Sector:** Research
- **Industry code:** NAICS 541714, 325412, SIC 2834
- **Region:** England
- **Revenue:** 503k a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/omass-therapeutics)

## Research in United Kingdom

Startups like it

- [**Isomorphic Labs** London · founded 2021 *Raised*](https://millionrounds.com/company/isomorphic-labs)
- [**Basecamp Research** London · founded 2019 *Raised*](https://millionrounds.com/company/basecamp-research)
- [**Callosum** London · founded 2025 *Raised*](https://millionrounds.com/company/callosum)
- [**Artios** Babraham · founded 2016 *Raised*](https://millionrounds.com/company/artios)
- [**First Light Fusion** Yarnton · founded 2011 *Raised*](https://millionrounds.com/company/first-light-fusion)
- [**IMU Biosciences** London · founded 2019 *Raised*](https://millionrounds.com/company/imu-biosciences)
- [**Orbital Industries** London · founded 2022 *Raised*](https://millionrounds.com/company/orbital-industries)
- [**Genomics** Oxford · founded 2014 *Raised*](https://millionrounds.com/company/genomics)

## Is this your company?

Add your raise, your deck and your story, and put OMass Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)